One source of relief for moderate to severe acute pain
NUCYNTA® (tapentadol), designed as a novel short‑acting opioid, offers the same active molecule as NUCYNTA® ER (tapentadol) extended‑release tablets, CII

POWERFUL EFFICACY



See phase 3 data demonstrating the strength of NUCYNTA for patients with moderate to severe acute pain.

LEARN MORE

CO‑PAY SAVINGS
AVAILABLE



Learn about our co‑pay savings offer for your commercially‑insured patients.

LEARN MORE